Proactive Investors - Run By Investors For Investors

Lojuxta 'exceeding expectations' - Amryt Pharma's Joe Wiley

Joe Wiley, chief executive of Amryt Pharma PLC (LON:AMYT) tells Proactive a product that it licensed the rights to is performing better than expected.

Lojuxta treats a rare and life-threatening condition called Homozygous Familial Hypercholesterolemia, which causes abnormally high levels of bad cholesterol.

Revenues from the treatment were €5.75mln for the six months ended June; the company’s total sales for the period were €6.18mln.

 
Meet Alliance Pharma PLC, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event, London , 24 January 2019. Register here »
View full AMYT profile View Profile

Amryt Pharma PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use